Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

OW 2026 15 November 2026

Impact of Oral Semaglutide 25 mg on Patient-Reported Daily Activities: IWDAQ Outcomes from OASIS 4

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Obesity
Congress poster
GLP-1 RA
GLP-1 RA
PHASE 3 (RCT)